Revolution Medicines, Inc. (RVMD) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Revolution Medicines reported revenue of $0. Net income was -$1.13B, or -$5.95 per diluted share. Operating activities generated -$897.7M of cash, leaving -$913.7M of free cash flow. At fiscal year end, Revolution Medicines held $2.35B in total assets against $723.2M in total liabilities, including $383.7M of cash and equivalents.
Open the full interactive Revolution Medicines financials → Quarterly statements, key ratios, valuation history and price charts.
Revolution Medicines Key Stats
| Share Price | $188.44 |
|---|---|
| Market Cap | $39.74B |
| 52-Week Range | $47.50 – $221.15 |
| Shares Outstanding | 210.9 million (basic, 2026 Q2) |
Revolution Medicines Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $43.0M | $29.4M | $35.4M | $11.6M | $0 | $0 |
| Operating Income | -$110.7M | -$188.0M | -$258.3M | -$487.2M | -$689.5M | -$1.18B |
| Pre-Tax Income | -$108.5M | -$187.1M | -$249.1M | -$439.9M | -$600.8M | -$1.13B |
| Income Tax | -$371,000 | $0 | -$420,000 | -$3.5M | -$753,000 | $0 |
| Net Income | -$108.2M | -$187.1M | -$248.7M | -$436.4M | -$600.1M | -$1.13B |
| Diluted EPS | -$2.01 | -$2.57 | -$3.08 | -$3.86 | -$3.58 | -$5.95 |
Revolution Medicines Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$305.2M | -$364.9M | -$453.8M | -$644.4M |
| Diluted EPS | -$1.61 | -$1.92 | -$2.29 | -$3.06 |
Revolution Medicines Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.3M | $108.5M | $161.4M | $696.1M | $543.1M | $383.7M |
| Current Assets | $454.1M | $589.8M | $660.2M | $1.88B | $2.33B | $2.08B |
| Total Assets | $567.4M | $738.0M | $811.9M | $2.06B | $2.56B | $2.35B |
| Current Liabilities | $47.2M | $60.4M | $62.0M | $143.9M | $163.9M | $290.4M |
| Total Liabilities | $92.7M | $135.4M | $126.7M | $235.5M | $293.1M | $723.2M |
| Shareholders' Equity | $474.7M | $602.6M | $685.2M | $1.83B | $2.27B | $1.63B |
Revolution Medicines Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$100.1M | -$147.2M | -$224.4M | -$350.6M | -$557.4M | -$897.7M |
| Cash From Investing | -$234.2M | -$142.1M | -$24.1M | -$342.6M | -$554.4M | $118.1M |
| Cash From Financing | $422.8M | $294.2M | $301.4M | $1.23B | $959.4M | $621.5M |
| Free Cash Flow | -$103.0M | -$153.7M | -$235.2M | -$358.3M | -$567.7M | -$913.7M |
| Dividends Paid | $0 | — | — | — | — | — |
Figures from Revolution Medicines' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Revolution Medicines financials page for every line item.
Revolution Medicines Company Profile
| Ticker | RVMD |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001628171 |
Frequently Asked Questions
What was Revolution Medicines' revenue in fiscal 2025?
Revolution Medicines (RVMD) reported revenue of $0 for fiscal 2025.
What is Revolution Medicines' annual revenue history?
Revolution Medicines' annual revenue by fiscal year: 2020: $43.0M; 2021: $29.4M; 2022: $35.4M; 2023: $11.6M; 2024: $0; 2025: $0.
What was Revolution Medicines' net income in fiscal 2025?
Revolution Medicines reported net income of -$1.13B for fiscal 2025.
What was Revolution Medicines' earnings per share (EPS) in fiscal 2025?
Revolution Medicines' diluted EPS was -$5.95 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Revolution Medicines generate in fiscal 2025?
Revolution Medicines generated -$913.7M of free cash flow in fiscal 2025.
What was Revolution Medicines' revenue last quarter?
In its most recent reported quarter (2026 Q2), Revolution Medicines reported revenue of $0.
How many shares of Revolution Medicines are outstanding?
Revolution Medicines reported a weighted average of 210.9 million basic shares outstanding in 2026 Q2.
What is Revolution Medicines' market cap?
Based on its latest closing price, Revolution Medicines (RVMD) has a market capitalization of about $39.74B.
When does Revolution Medicines' fiscal year end?
Revolution Medicines' fiscal year end, as registered with the SEC, is December 31.
Where is Revolution Medicines headquartered?
Revolution Medicines lists its business address in Redwood City, California in its SEC filings.
Revolution Medicines Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →